2026 KRAS G12C-mutant non-small cell lung cancer strategy: epidemiology, KRAS G12C biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Squamous non-small cell lung cancer strategy: epidemiology, PD-1 biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Cutaneous squamous cell carcinoma strategy: epidemiology, PD-1 biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Basal cell carcinoma strategy: epidemiology, SMO biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Upanovimab, an antibody targeting SARS-CoV-2 Spike RBD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Romlusevimab, an antibody targeting SARS-CoV-2 Spike RBD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ogalvibart, an antibody targeting SARS-CoV-2 Spike RBD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Luveltamab, an antibody targeting Folate receptor alpha.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lomtegovimab, an antibody targeting SARS-CoV-2 Spike RBD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Livmoniplimab, an antibody targeting LRRC32.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Crexavibart, an antibody targeting SARS-CoV-2 Spike RBD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Adintrevimab, an antibody targeting SARS-CoV-2 Spike.